{"url_path":"/sec/pets/10-k/2026/item-5","section_key":"item-5","section_title":"Item 5 MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED SHAREHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES","topic":"sec","document":{"doc_type":"10-K","doc_date":"2026-06-02","source_url":"https://www.sec.gov/Archives/edgar/data/1040130/0001040130-26-000019-index.html","accession_number":"0001040130-26-000019","cik":"0001040130","ticker":"PETS","issuer_name":"PETMED EXPRESS INC","edgar_url":"https://www.sec.gov/Archives/edgar/data/1040130/0001040130-26-000019-index.html","primary_entity_key":"0001040130","primary_entity_name":"PETMED EXPRESS INC"},"word_count":574,"has_tables":true,"body_markdown":"ITEM 5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED SHAREHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES\n\nMarket Information\n\nOur common stock is traded on the NASDAQ Global Select Market (“NASDAQ”) under the symbol “PETS.”\n\nHolders\n\nThere were 130 active holders of record of our common stock on May 22, 2026.\n\nDividend Policy\n\nOn October 26, 2023, our Board of Directors elected to suspend the quarterly dividend for the second quarter of fiscal year 2024, and on February 1, 2024, our Board of Directors elected to suspend the quarterly dividend indefinitely. This move is intended to focus use of the Company’s existing cash flow on growth and other higher return initiatives. The Board of Directors reviews and discusses the capital allocation needs of the Company, at a minimum, on a quarterly basis. The declaration and payment of future dividends is discretionary and will be subject to a determination by the Board of Directors. When considering whether to declare a dividend, our Board of Directors will take into account:\n\n• General economic and business conditions;\n\n• Our financial condition and operating results;\n\n• Our available cash and current and anticipated cash needs;\n\n• Our capital requirements;\n\n• Strategic uses of cash for growth initiatives;\n\n• Contractual, legal, tax and regulatory restrictions on the payment of dividends by us; and\n\n• Such other factors as our Board of Directors may deem relevant.\n\nPerformance Graph\n\nSet forth below is a line graph comparing the five-year cumulative performance of our common stock with the NASDAQ Composite, the Russell 2000, and S&P 500 from March 31, 2021 to March 31, 2026. The graph assumes that $100 was invested on March 31, 2021, in each of our Common Stock, the NASDAQ Composite, the Russell 2000, and the S&P 500. Because we have historically paid dividends on a quarterly basis, the graph assumes that dividends were reinvested. The performance graph and related information below shall not be deemed “filed” with the SEC, nor shall such\n\n26\n\ninformation be incorporated by reference into any future filing under the Securities Act or Exchange Act, except to the extent that we specifically incorporate it by reference into such filing.\n\nPerformance graph data:\n\nFiscal Year Ended March 31,\n\n202120222023202420252026\n\nPetMed Express, Inc.100.0076.5851.1215.7513.777.50\n\nNASDAQ Composite100.00107.3592.26123.65130.59162.99\n\nS&P 500\n100.00114.03103.43132.26141.25164.33\n\nRussell 2000100.0093.2381.1795.6890.61112.42\n\n27\n\nSecurities Authorized for Issuance under Equity Compensation Plans\n\nThe following table sets forth securities authorized for issuance under equity compensation plans, including individual compensation arrangements, by us under our 2015 Outside Director Equity Compensation Plan, 2016 Employee Equity Compensation Restricted Stock Plan, 2022 Employee Equity Compensation Plan, 2024 Omnibus Incentive Plan and 2024 Inducement Incentive Plan as of March 31, 2026:\n\nPlan categoryNumber of securities to be issued upon exercise of outstanding options, warrants and rightsWeighted average exercise price of outstanding options, warrants and rightsNumber of securities remaining available for further issuance under equity compensation plans\n\nEquity Compensation Plans Approved by Equity Holders\n\n2015 Outside Director Equity Compensation Plan2,500— — \n\n2016 Employee Equity Compensation Restricted Stock Plan— — — \n\n2022 Employee Equity Compensation Plan52,037— — \n\n2024 Omnibus Incentive Plan92,317— 1,483,199(1)\n\nTotal\n146,8541,483,199\n\nEquity Compensation Plans Not Approved by Equity Holders\n\n2024 Inducement Incentive Plan26,667— 201,265\n\nTotal for All Plans173,521— 1,684,464\n\n(1) On the August 8, 2024 adoption date of the 2024 Omnibus Incentive plan, the shares then available for future grant under 2015 Outside Director Equity Compensation Plan and 2022 Employee Equity Compensation Plan were added to the initial reserve under the 2024 Omnibus Incentive Plan."}